A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for Moderately to Severely Active Crohns Disease
Drug: Afimkibart
92 locations incl. Dothan
Sponsor: Hoffmann-La Roche
Sex: All·Age: 16 - 80
Code: NCT06819878·Phase 3·Recruiting